COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Baxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Tau​2 = 0.00; I​2 = 0.0%Early treatment81%0.19 [0.10-0.37]6/40940/39881% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies71%0.29 [0.16-0.54]48/1,144104/1,01771% improvement7 povidone-iodine COVID-19 studiesc19pvpi.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.20; I​2 = 34.1%; Z = 3.97Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]2/30317/303Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment88%0.12 [0.03-0.50]2/30317/30388% improvementAll studies88%0.12 [0.03-0.50]2/30317/30388% improvement1 povidone-iodine COVID-19 mortality resultc19pvpi.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.88Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)84%0.16 [0.09-0.28]hosp.12/30377/303Improvement, RR [CI]TreatmentControlBaxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Tau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.09-0.29]12/34078/34584% improvementAll studies84%0.16 [0.09-0.29]12/34078/34584% improvement2 povidone-iodine COVID-19 hospitalization resultsc19pvpi.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 6.22Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Improvement, RR [CI]TreatmentControlBaxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Tau​2 = 0.00; I​2 = 0.0%Early treatment86%0.14 [0.04-0.53]2/34018/34586% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies67%0.33 [0.11-1.01]44/1,07582/96467% improvement3 povidone-iodine COVID-19 serious outcomesc19pvpi.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.52; I​2 = 51.4%; Z = 1.95Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Seet (CLUS. RCT)31%0.69 [0.37-1.01]338/735433/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP31%0.69 [0.37-1.01]338/735433/61931% improvementAll studies31%0.69 [0.63-0.76]338/735433/61931% improvement1 povidone-iodine COVID-19 case resultc19pvpi.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 7.77Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)96%0.04 [0.02-0.07]8/303213/303Elzein (DB RCT)89%0.11 [0.01-1.00]25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]4/2719/27Tau​2 = 0.77; I​2 = 66.2%Early treatment91%0.09 [0.03-0.30]12/360235/34491% improvementAll studies91%0.09 [0.03-0.30]12/360235/34491% improvement4 povidone-iodine COVID-19 viral clearance resultsc19pvpi.com Aug 29, 2021Tau​2 = 0.77; I​2 = 66.2%; Z = 4.06Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Baxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Tau​2 = 0.00; I​2 = 0.0%Early treatment81%0.19 [0.10-0.37]6/40940/39881% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies71%0.29 [0.16-0.54]48/1,144104/1,01771% improvement7 povidone-iodine COVID-19 Randomized Controlled Trialsc19pvpi.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.20; I​2 = 34.1%; Z = 3.97Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]2/30317/303Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment88%0.12 [0.03-0.50]2/30317/30388% improvementAll studies88%0.12 [0.03-0.50]2/30317/30388% improvement1 povidone-iodine COVID-19 RCT mortality resultc19pvpi.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.88Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Choudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Improvement, RR [CI]TreatmentControlGuenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Tau​2 = 0.00; I​2 = 0.0%Early treatment81%0.19 [0.10-0.38]6/36736/35181% improvementSeet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP45%0.55 [0.38-0.80]42/73564/61945% improvementAll studies72%0.28 [0.14-0.58]48/1,102100/97072% improvement5 povidone-iodine COVID-19 peer reviewed trialsc19pvpi.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.32; I​2 = 52.8%; Z = 3.43Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Mohamed (RCT)86%0.14 [0.01-2.21]viral+0/53/5Improvement, RR [CI]TreatmentControlChoudhury (RCT)88%0.12 [0.03-0.50]death2/30317/303Choudhury (RCT)84%0.16 [0.09-0.28]hosp.12/30377/303Choudhury (RCT)96%0.04 [0.02-0.07]viral+8/303213/303Guenezan (RCT)63%0.37 [0.06-1.63]viral load12 (n)12 (n)Elzein (DB RCT)89%0.11 [0.01-1.00]viral load25 (n)9 (n)Arefin (RCT)79%0.21 [0.08-0.54]viral+4/2719/27Arefin (RCT)89%0.11 [0.03-0.41]viral+2/2719/27Arefin (RCT)53%0.47 [0.26-0.85]viral+9/2719/27Arefin (RCT)80%0.20 [0.09-0.44]viral+5/2725/27Arefin (RCT)64%0.36 [0.21-0.62]viral+9/2725/27Arefin (RCT)74%0.26 [0.19-0.37]viral+29/13544/54Baxter (RCT)65%0.35 [0.01-8.27]hosp.0/371/42OT​1Baxter (RCT)79%0.21 [0.01-4.24]hosp./ER0/372/42OT​1Baxter (RCT)56%0.44 [0.20-0.94]no recov.6/2518/33OT​1Seet (CLUS. RCT)45%0.55 [0.38-0.80]severe case42/73564/619OT​1Seet (CLUS. RCT)31%0.69 [0.37-1.01]cases338/735433/619OT​1povidone-iodine COVID-19 outcomesc19pvpi.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home